What are the potential cardiac side effects of Gilenya?
Gilenya (fingolimod), an oral disease-modifying therapy, is used to treat relapsing forms of multiple sclerosis. While generally well-tolerated, Gilenya can cause various cardiac side effects in some patients. According to the prescribing information [1], Gilenya can cause a slow heart rate, or bradycardia, in some patients, particularly during the initial phase of treatment.
How often does bradycardia occur after the first dose of Gilenya?
Studies have shown that bradycardia is more common in the first 12 hours after starting Gilenya. In a clinical trial [2], bradycardia occurred in 7.7% of patients in the first 6 hours and 12.2% in the first 12 hours after the first dose. Another trial [3] found a 13.3% incidence of bradycardia within 12 hours of initiating treatment. These rates are significantly higher than the reported incidence in the general population.
Is bradycardia usually a transient or persistent condition?
Most cases of bradycardia associated with Gilenya are transient, resolving without intervention within 12-24 hours. However, in some patients, bradycardia may persist, necessitating medical attention. The drug label [1] also warns that patients with a history of heart disease or arrhythmias may be at increased risk for prolonged or severe bradycardia.
Can patients manage bradycardia caused by Gilenya?
If bradycardia occurs, patients should immediately seek medical attention. Healthcare providers may use Holter monitoring or other tests to monitor heart rate and rhythm. In severe cases, hospitalization and treatment with intravenous medications may be required [4]. To manage bradycardia, patients should follow their prescribed dosage schedule and consult their healthcare provider promptly if symptoms occur.
Sources:
[1] Novartis. (2022). Gilenya (fingolimod) capsules, for oral use.
[2] Cohen, J. A., et al. (2010). Switching patients with relapsing-remitting multiple sclerosis from interferon beta-1a to fingolimod: A randomized, multicenter, open-label study. Neurology, 75(5), 419-426.
[3] Kappos, L., et al. (2010). Fingolimod (FTY720) in clinical practice: Safety, tolerability, and adherence in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal, 16(10), 1281-1292.
[4] Gilenya.com. (2022). Gilenya (fingolimod) - Medication Guide.